
    
      Patients are randomly placed into 1 of 6 groups: 4 dose levels of T-20 are given by
      subcutaneous infusion and 2 by subcutaneous injection. The entire study lasts 7 weeks;
      including a 2-week screening period, followed by 28 days of treatment and 1 week of
      follow-up.
    
  